Search

Displaying results 1811 - 1820 of 5758 in total
  1. Drug

    Fibrinogen human

    go.drugbank.com/drugs/DB09222
    ApprovedInvestigational

    Fibrinogen concentrate (human) is a hematological agent. It works by replacing a specific protein in the blood, fibrinogen (factor I), that helps with blood clotting. It is a soluble plasma glycoprotein with a molecular weight of about 3...

    Mixtures: BERIPLAST-P COMBI SET 1 ML TROMBİN ÇÖZELTİSİ VE 1 ML FİBRİNOJEN ÇÖZELTİSİ İÇEREN FİBRİN YAPIŞTIRICI, BERIPLAST-P COMBI SET 3 ML TROMBİN ÇÖZELTİSİ VE 1 ML FİBRİNOJEN ÇÖZELTİSİ İÇEREN FİBRİN YAPIŞTIRICIProducts: VERASEAL SOLUTIONS FOR SEALANT, 80 mg/ml, 500 IU/ml, HAEMOCOMPLETTAN-P 1G IV ENJEKSİYONLUK/İNFÜZYONLUK ÇÖZELTİ TOZU
  2. Drug

    Silicon

    go.drugbank.com/drugs/DB12982
    Approved

    Silicon is under investigation in clinical trial NCT00103246 (Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides).

    Mixtures: Calcium With Mg Zn Mn Cu CR Si and Vit. C & D
  3. Target

    Gremlin-1

    go.drugbank.com/bio_entities/BE0011799
    TargetHumans

    Cytokine that may play an important role during carcinogenesis and metanephric kidney organogenesis, as a BMP antagonist required for early limb outgrowth and patterning in maintaining the FGF4-SHH feedback loop. Down-regulates the BMP4 ...

    Synonyms: DAN domain family member 2
  4. Drug

    Fenoterol

    go.drugbank.com/drugs/DB01288
    ApprovedWithdrawn

    Fenoterol is an adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.

    Synonyms: 3,5-dihydroxy-α-(((p-hydroxy-α-methylphenethyl)amino)methyl)benzyl alcohol, 1-(p-hydroxyphenyl)-2-((β-hydroxy-β-(3',5'-dihydroxyphenyl))ethyl)aminopropaneInternational brands: Berotec N
  5. Drug

    Acalabrutinib

    go.drugbank.com/drugs/DB11703
    ApprovedInvestigational

    To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administer...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors
  6. Drug

    Deucravacitinib

    go.drugbank.com/drugs/DB16650
    ApprovedInvestigational

    Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. Unlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regula...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  7. Drug

    Gavestinel

    go.drugbank.com/drugs/DB06741
    Experimental

    Highly potent and selective non-competitive antagonist acting at the strychnine-insensitive glycine binding site of the NMDA receptor-channel complex (Kd = 0.8 nM).

  8. Drug

    AdimrSC-2f

    go.drugbank.com/drugs/DB16436
    Investigational

    The AdimrSC-2f (SARS-CoV-2) vaccine is developed through Adimmune Corporation, the only influenza vaccine manufacturer with both EU GMP and US FDA certification in Asia[L30553].

  9. Drug

    CHF 4227

    go.drugbank.com/drugs/DB05882
    Experimental

    Additionally, the compound has shown no uterotrophic activity suggesting a potential therapeutic advantage over drugs normally used in postmenopausal therapy.

  10. Drug

    Indolidan

    go.drugbank.com/drugs/DB19499
    Experimental

    The usage of the INN stem '-dan' in the name indicates that Indolidan is a cardiac stimulant, pimobendan derivative. Indolidan has a monoisotopic molecular weight of 257.12 Da.